Compare OBLG & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OBLG | GNPX |
|---|---|---|
| Founded | 2000 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 6.5M |
| IPO Year | N/A | 2018 |
| Metric | OBLG | GNPX |
|---|---|---|
| Price | $2.26 | $3.37 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 76.4K | ★ 366.8K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,378,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.69 | $2.61 |
| 52 Week High | $5.50 | $63.00 |
| Indicator | OBLG | GNPX |
|---|---|---|
| Relative Strength Index (RSI) | 47.51 | 48.04 |
| Support Level | $1.98 | $2.61 |
| Resistance Level | $2.25 | $5.00 |
| Average True Range (ATR) | 0.23 | 0.40 |
| MACD | 0.05 | -0.11 |
| Stochastic Oscillator | 68.31 | 38.83 |
Oblong Inc is a provider of patented multi-stream collaboration products and managed services for network solutions and video collaboration. The company's flagship product Mezzanine is the technology platform that defines computing: simultaneous multi-user, multi-screen, multi-device, and multi-location for dynamic and immersive visual collaboration. Mezzanine transforms routine meetings and workflows into agile, engaging experiences by making data visible and accessible in a collaborative setting. The mezzanine enables multiple, concurrent pieces of content to be shared, manipulated, created, and captured across distance. It serves various industries including aerospace, consulting, executive search, broadcast media, technology, financial services, education, healthcare, and real estate.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.